PubMed
Cagrilintide plus semaglutide for obesity: a randomized phase 2 trial
Frias JP, Deenadayalan S, Erichsen L, et al. Nat Med. 2023
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 60% · Mixed 26% · Unfavorable overall 14%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.1–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 40% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 20 days · Based on 54 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 45% · Mixed 38% · Unfavorable overall 17%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.025–2 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 31% more positive, and 15% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 14 days · Based on 84 repeat reporters
Published sources linked on the CagriSema and Retatrutide wiki pages.
PubMed
Frias JP, Deenadayalan S, Erichsen L, et al. Nat Med. 2023
PubMed
Rosenstock J, Frias J, Jastreboff AM, et al. Lancet. 2023
PubMed
Jastreboff AM, Kaplan LM, Frias JP, et al. N Engl J Med. 2023
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Jastreboff AM, Kaplan LM, Frías JP, et al. The New England journal of medicine. 2023
PubMed
Katsi V, Koutsopoulos G, Fragoulis C, et al. Biomolecules. 2025